Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation

  • Claudia Karnthaler-Benbakka
  • , Diana Groza
  • , Kushtrim Kryeziu
  • , Verena Pichler
  • , Alexander Roller
  • , Walter Berger
  • , Petra Heffeter (Corresponding author)
  • , Christian R. Kowol

Publications: Contribution to journalArticlePeer Reviewed

Original languageEnglish
Pages (from-to)12930-12935
Number of pages6
JournalAngewandte Chemie (International Edition)
Volume53
Issue number47
DOIs
Publication statusPublished - 17 Nov 2014

Funding

This work was supported by the Fonds der Stadt Wien fur innovative interdisziplinaere Krebsforschung, the FWF (P26603), and the COST action CM1105. We thank Prof. Mag. Dr. Walter Weissensteiner, University of Vienna, for helpful discussions. The authors declare a conflict of interest, as the lead compound is covered by a patent application.

Austrian Fields of Science 2012

  • 104003 Inorganic chemistry
  • 301904 Cancer research

Keywords

  • anticancer drugs
  • cobalt
  • hypoxia
  • prodrugs
  • tyrosine-kinase inhibitors
  • RECEPTOR TYROSINE KINASE
  • METAL-COMPLEXES
  • CANCER
  • PRODRUG
  • DERIVATIVES
  • THERAPY
  • AGENTS
  • Prodrugs
  • Anticancer drugs
  • Tyrosine-kinase inhibitors
  • Cobalt
  • Hypoxia

Fingerprint

Dive into the research topics of 'Tumor-Targeting of EGFR Inhibitors by Hypoxia-Mediated Activation'. Together they form a unique fingerprint.

Cite this